Ocugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock

StreetInsider2021-02-11

MALVERN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

bounceback
2021-02-16
bounceback
Bad management .. why always offering ?
- Zenkyn:
  Pleasr like and comment
- Jonathan18s:
  The company wants to take in some cash to grow or profit taking
WW1012
2021-02-15
WW1012
Boom?
WSBApes
2021-02-15
WSBApes
Pls like and comment
- Dinorawrr:
  hdhhwjd
- WSBApes:
  hjj
- WSBApes:
  ghhhmkjg
- WSBApes:
  nice thanks
eieicp
2021-02-14
eieicp
I sold liao
- Nobi:
  why leh
Flubber
2021-02-14
Flubber
Comment comment
- Flubber:
  Comment
MaxLYT
2021-02-13
MaxLYT
Like pls

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2110049361?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-02-11 10:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2110049361","market":"us","top_or_hot":-1,"title":"Ocugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock","media":"StreetInsider","content":"<div>\n<p>MALVERN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=17951558\">网页链接</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-11 10:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=17951558><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>MALVERN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=17951558\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TERN","symbol_name":"Terns Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=17951558","article_id":"2110049361","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2110049361","pubTimestamp":1613008800,"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"MALVERN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical com","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TERN":"Terns Pharmaceuticals, Inc."},"translate_title":"Ocugen公司宣布完成2300万美元注册直接发行普通股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TERN":0.9},"content_text":"MALVERN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it has closed the previously announced registered direct offering for the sale of an aggregate of 3,000,000 shares of its common stock for gross proceeds of approximately $23 million, prior to deducting placement agent’s fees and other offering expenses payable by Ocugen.\nH.C. Wainwright & Co. acted as the exclusive placement agent for the offering.\nOcugen intends to use the net proceeds from the offering for general corporate purposes, capital expenditures, working capital and general and administrative expenses.\nThe shares of common stock described above were offered pursuant to a “shelf” registration statement (File No. 333-237456) filed with the Securities and Exchange Commission (“SEC”) on March 27, 2020 and declared effective on May 5, 2020. Such shares of common stock were offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock was filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock may be obtained on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail: placements@hcwco.com or by telephone: (646) 975-6996.\nThis press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.\nAbout Ocugen, Inc.\nOcugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many,” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":382838387,"gmtCreate":1613405602649,"gmtModify":1634553747609,"author":{"id":"3571841084298801","authorId":"3571841084298801","name":"bounceback","avatar":"https://static.tigerbbs.com/d22690e86815acbf89a434dd51da5a0c","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"Bad management .. why always offering ?","listText":"Bad management .. why always offering ?","text":"Bad management .. why always offering ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/382838387","repostId":2110049361,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3576050,"gmtCreate":1613435425181,"gmtModify":1635764129810,"authorId":3570509119176291,"author":{"id":3570509119176291,"authorId":3570509119176291,"name":"Zenkyn","avatar":"https://static.tigerbbs.com/192b5b1521b264f31a2685e7170d3cde","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":382838387,"type":1,"supId":0,"prevId":0,"content":"Pleasr like and comment ","text":"Pleasr like and comment ","html":"Pleasr like and comment "},{"id":3576322,"gmtCreate":1613438164968,"gmtModify":1635764115434,"authorId":3570619809520803,"author":{"id":3570619809520803,"authorId":3570619809520803,"name":"Jonathan18s","avatar":"https://static.tigerbbs.com/e6648649393c154a8d4835022ee3b55d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":382838387,"type":1,"supId":0,"prevId":0,"content":"The company wants to take in some cash to grow or profit taking","text":"The company wants to take in some cash to grow or profit taking","html":"The company wants to take in some cash to grow or profit taking"}],"langContent":"EN"},{"id":382325081,"gmtCreate":1613367442643,"gmtModify":1634553836764,"author":{"id":"3553224628095486","authorId":"3553224628095486","name":"WW1012","avatar":"https://static.tigerbbs.com/f992cdfebad899a930707fdd9a236024","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Boom?","listText":"Boom?","text":"Boom?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/382325081","repostId":2110049361,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":382300240,"gmtCreate":1613356832080,"gmtModify":1634553877675,"author":{"id":"3554966404999750","authorId":"3554966404999750","name":"WSBApes","avatar":"https://static.tigerbbs.com/524d2f8eb87bb134321ff44e82807a56","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"Pls like and comment","listText":"Pls like and comment","text":"Pls like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/382300240","repostId":2110049361,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3572433,"gmtCreate":1613357267030,"gmtModify":1635764288972,"authorId":3554985094748884,"author":{"id":3554985094748884,"authorId":3554985094748884,"name":"Dinorawrr","avatar":"https://static.tigerbbs.com/1fb9df44b170a8dd8de17480623183c7","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":382300240,"type":1,"supId":0,"prevId":0,"content":"<u>hdhhwjd</u>","text":"<u>hdhhwjd</u>","html":"<u>hdhhwjd</u>"},{"id":3572437,"gmtCreate":1613357321134,"gmtModify":1635764288863,"authorId":3554966404999750,"author":{"id":3554966404999750,"authorId":3554966404999750,"name":"WSBApes","avatar":"https://static.tigerbbs.com/524d2f8eb87bb134321ff44e82807a56","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":382300240,"type":1,"supId":3572433,"prevId":0,"content":"<u>hjj</u>","text":"<u>hjj</u>","html":"<u>hjj</u>"},{"id":3572439,"gmtCreate":1613357340897,"gmtModify":1635764288644,"authorId":3554966404999750,"author":{"id":3554966404999750,"authorId":3554966404999750,"name":"WSBApes","avatar":"https://static.tigerbbs.com/524d2f8eb87bb134321ff44e82807a56","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":382300240,"type":1,"supId":3572433,"prevId":0,"content":"<u>ghhhmkjg</u>","text":"<u>ghhhmkjg</u>","html":"<u>ghhhmkjg</u>"},{"id":3572448,"gmtCreate":1613357403118,"gmtModify":1635764287991,"authorId":3554966404999750,"author":{"id":3554966404999750,"authorId":3554966404999750,"name":"WSBApes","avatar":"https://static.tigerbbs.com/524d2f8eb87bb134321ff44e82807a56","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":382300240,"type":1,"supId":3572433,"prevId":0,"content":"nice thanks","text":"nice thanks","html":"nice thanks"}],"langContent":"EN"},{"id":386769151,"gmtCreate":1613276241473,"gmtModify":1634554035539,"author":{"id":"3570343636470488","authorId":"3570343636470488","name":"eieicp","avatar":"https://static.tigerbbs.com/6b181d159c585aebcd525b8e5525cf06","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"I sold liao","listText":"I sold liao","text":"I sold liao","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/386769151","repostId":2110049361,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3570923,"gmtCreate":1613315688715,"gmtModify":1635764356290,"authorId":3573809317992460,"author":{"id":3573809317992460,"authorId":3573809317992460,"name":"Nobi","avatar":"https://static.tigerbbs.com/f6f79f8404d0e36885a520438a78cd94","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":386769151,"type":1,"supId":0,"prevId":0,"content":"why <u>leh</u>","text":"why <u>leh</u>","html":"why <u>leh</u>"}],"langContent":"EN"},{"id":386718627,"gmtCreate":1613273197269,"gmtModify":1634554048239,"author":{"id":"3573767689206643","authorId":"3573767689206643","name":"Flubber","avatar":"https://static.tigerbbs.com/0e7f3647f5821119256727646e2c812f","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Comment comment","listText":"Comment comment","text":"Comment comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/386718627","repostId":2110049361,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3568966,"gmtCreate":1613273214652,"gmtModify":1635764437298,"authorId":3573767689206643,"author":{"id":3573767689206643,"authorId":3573767689206643,"name":"Flubber","avatar":"https://static.tigerbbs.com/0e7f3647f5821119256727646e2c812f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":386718627,"type":1,"supId":0,"prevId":0,"content":"Comment","text":"Comment","html":"Comment"}],"langContent":"EN"},{"id":386494019,"gmtCreate":1613230908131,"gmtModify":1634554116788,"author":{"id":"3572199670660801","authorId":"3572199670660801","name":"MaxLYT","avatar":"https://static.tigerbbs.com/dc1fd1bde60ff7a3573df4f9c645256e","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like pls&nbsp;","listText":"Like pls&nbsp;","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/386494019","repostId":2110049361,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":26,"commentSize":15,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2110049361"}